Anti-Human/Mouse Integrin β7 - PE

Integrin α4β7 is expressed on subsets of peripheral lymphocytes, thymocytes, and bone marrow progenitors. The αEβ7 integrin is expressed on mucosal T cells, including intraepithelial T lymphocytes (IELs) and lamina propria T cells, subsets of dendritic cells, and regulatory T cells (Tregs)8.

0.2 mg/ml

R-phycoerythrin (PE)

This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

TK1 Cells

Integrin β7 antibody, clone FIB504, recognizes integrin β7, a 130 kDa membrane glycoprotein of the Ig superfamily. Integrin β7 forms heterodimers with both the α4 (CD49d) and aE (CD103) integrins. α4β7 integrin is expressed on subsets of peripheral lymphocytes, thymocytes, and bone marrow progenitors1,2. It mediates adhesion to mucosal endothelial cells, promoting leukocyte transendothelial migration through interactions with mucosal addressin cell adhesion molecule-1 (MAdCAM-1)3,4. The αEβ7 integrin is expressed on mucosal T cells, including intraepithelial T lymphocytes (IELs) and lamina propria T cells5,6, subsets of dendritic cells7, and regulatory T cells (Tregs)8. It facilitates retention in the gut epithelial layer via interactions with E-cadherin9. Anti-β7 antibodies block both the homing to and retention in the gut of pathogenic T cells10 and are currently under evaluation in a phase 3 clinical trial to treat inflammatory bowel disease11.

16421

Integrin Beta 7